PYFAGROUP’s Commitment to the Nation’s Health is Realized Through the Expansion of Ethica Industri Farmasi’s Injection Production Facility
Jakarta, September 12, 2024 – PT Ethica Industri Farmasi, a pharmaceutical company under the PYFAGROUP, has officially commenced the groundbreaking ceremony for the expansion of its injection production facility. With significant investments, Ethica Industri Farmasi is committed to increasing its production capacity by up to three times.
This facility expansion will be equipped with advanced and modern production technology, meeting both domestic and international Current Good Manufacturing Practices (cGMP) standards, including the PIC/S guidelines, as well as the requirements of the European Union Good Manufacturing Practices (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia. This demonstrates Ethica Industri Farmasi’s readiness to penetrate a wider global market.
“The increasing demand for injectable products is the primary motivation for us to expand and meet the needs of rapidly growing hospitals in recent years,” said Merciana Evy, President Director of PT Ethica Industri Farmasi. “As part of the PYFAGROUP family, we remain committed to innovating and making a greater contribution to the Indonesian pharmaceutical industry. With increased production capacity, we are ready to meet the demand for high-quality medicines, both domestically and internationally.”
With this expansion, Ethica Industri Farmasi further strengthens its position as one of the leading pharmaceutical companies in Indonesia. The company is poised to become a key player in the global pharmaceutical industry, with a focus on developing and producing innovative medicines.
